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Background: Surfactant protein D (SP-D) can regulate both innate and adaptive immunity. Recently, SP-D has been
shown to contribute to the pathogenesis of airway allergic inflammation and bleomycin-induced pulmonary fibrosis.
However, in allergic airways disease, the role of SP-D in airway remodeling remains unknown. The objective of this
study was to determine the contribution of functional SP-D in regulating sub-epithelial fibrosis in a mouse chronic
house dust mite model of allergic airways disease.
Methods: C57BL/6 wild-type (WT) and SP-D−/− mice (C57BL/6 background) were chronically challenged with
house dust mite antigen (Dermatophagoides pteronyssinus, Dp). Studies with SP-D rescue and neutralization of TGF-β
were conducted. Lung histopathology and the concentrations of collagen, growth factors, and cytokines present in the
airspace and lung tissue were determined. Cultured eosinophils were stimulated by Dp in presence or absence of SP-D.
Results: Dp-challenged SP-D−/− mice demonstrate increased sub-epithelial fibrosis, collagen production, eosinophil
infiltration, TGF-β1, and IL-13 production, when compared to Dp-challenged WT mice. By immunohistology, we detected
an increase in TGF-β1 and IL-13 positive eosinophils in SP-D−/− mice. Purified eosinophils stimulated with Dp produced
TGF-β1 and IL-13, which was prevented by co-incubation with SP-D. Additionally, treatment of Dp challenged
SP-D−/− mice with exogenous SP-D was able to rescue the phenotypes observed in SP-D−/− mice and
neutralization of TGF-β1 reduced sub-epithelial fibrosis in Dp-challenged SP-D−/− mice.
Conclusion: These data support a protective role for SP-D in the pathogenesis of sub-epithelial fibrosis in a mouse
model of allergic inflammation through regulation of eosinophil-derived TGF-β.
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Surfactant is a lipoprotein complex that resides at the
air-liquid interface of the lungs and is most commonly
known for its role in reducing surface tension. Surfac-
tant is produced by alveolar type II cells and airway
Clara cells [1] and is composed of approximately 10%
proteins, which includes surfactant protein (SP)-A, SP-B,
SP-C and SP-D. SP-A and SP-D are members of collectin
family of proteins and can modulate innate immunity.
Previous reports have shown that SP-D can enhanced pul-
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unless otherwise stated.aerginosa [2], Klebsiella pneumonia [3], respiratory syn-
cytial virus (RSV) [4] and Influenza virus [5]. Furthermore,
SP-D has also been shown to modify allergic responses in
the lungs and can bind to several common allergens, in-
cluding house dust mite (Dermatophagoides pteronyssinus,
Dp) [6], Aspergillus fumigatus, (Af) [7] and pollen gran-
ules [8]. Additionally SP-D reduce airway hyperrespon-
siveness (AHR) and eosinophilia in either ovalbumin
(OVA) [9] or in Af [10] murine models of allergic airways
disease and SP-D administration after antigen challenge
can attenuate eosinophila and Th2 cytokine production in
Dp-sensitized mice [11-13]. While SP-D can attenuate
AHR and eosinophilia in these allergic models, the role of
SP-D in remodeling of the airways remains unexplored.
Airway remodeling is central to the pathogenesis of
asthma and can include sub-epithelial fibrosis, mucusLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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plasia. A better understanding of the factors that regulate
the pathogenesis of sub-epithelial fibrosis may provide an
opportunity for novel interventions in chronic bronchial
asthma. Previous work demonstrated that both SP-A and
SP-D can mitigate pulmonary fibrosis in mouse models of
lung injury. For example, SP-A-deficient and SP-D-
deficient mice are susceptible to bleomycin-induced lung
injury and display increased cellular inflammation, more
severe lung fibrosis, and reduced survival [14,15]. Studies
using the bleomycin lung fibrosis model support that SP-
D attenuate pulmonary fibrosis through both regulation of
TGF-β1 and PDGF-AA production, as well as, limiting
fibrocyte migration into the lung [16]. Clinical relevance
of these findings is supported by the association between
serum levels of either SP-A or SP-D and mortality in pa-
tients with pulmonary fibrosis [17,18].
Based on these previous observations, we used a model
of chronic exposure to Dp to test the hypothesis that SP-
D would attenuate the development of sub-epithelial fi-
brosis in an allergic airways disease. Present findings here
suggest that SP-D plays a protective role in allergic airways
by reducing the development of sub-epithelial fibrosis.
Materials and methods
Detailed methods are described in the supporting
information.Figure 1 Experimental mouse protocols. (A) Model of sensitization and ch
treatment model.Preparation of antigen
House-dust mite antigen (Dermatophagoides pteronyssi-
nus, Dp) was purchased from Cosmobio Ltd (Tokyo,
Japan). Endotoxin levels were reduced using endotoxin re-
moval solution (Sigma-Aldrich, Japan) to <0.02 EU/mg.
Animal protocol
All mouse studies were carried out in strict accordance
with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes
of Health. The protocol was approved by the Institute of
Animal Care and Use Committee (IACUC) at Duke Uni-
versity. All surgery was performed under Ketamine
(50 mg/kg)/Xylazine (5 mg/kg) anesthesia and all efforts
were made to minimize suffering.
SP-D knockout (SP-D−/−) mice (C57BL/6 background)
and IL-5 transgenic mice (C57BL/6 background) were
generated as previously described [19,20]. Wild-type
(WT) C57BL/6 mice were purchased from The Jackson
Laboratory and bred in-house to control for environmen-
tal conditions. 6–10 week old mice were sensitized and
challenged by Dp as described previously [21] (Figure 1).
3–5 mice per group were used in each experiment and
these experiments were repeated for 2–3 times. Data from
experiments were pooled for analysis. Bronchoalveolar
lavage (BAL) was performed and lungs were harvested for
histopathology and lung homogenization [21].ronic challenge to Dp (B) SP-D rescue model (C) Anti-TGF-β1 antibody
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Recombinant SP-D was isolated from Chinese hamster
ovary cells expressing rat SP-D protein as described
previously [22]. Recombinant SP-D (3 μg in 50 μl PBS)
or 50 μl PBS as control was administered into Dp-
challenged SP-D−/− mouse by oropharyngeal aspiration
as described previously [15,16] twice weekly from days
13 to 38 (Figure 1).Anti-TGF-β1 antibody administration in vivo
1.0 mg/kg of Anti-TGF-β1 antibody (R&D Systems,
Minneapolis, MN) or 1.0 mg/kg of IgG isotype antibody
(R&D Systems) as control was administered intraperito-
neally into Dp challenged WT and SP-D−/− mouse twice
weekly from days 14 to 37 (Figure 1).Eosinophil purification and in vitro experiment
Eosinophils were purified from blood of IL-5 transgenic
mouse as described previously and purity was deter-
mined to be greater than 95% [23]. Eosinophils (4x105)
were incubated in 48 well plates in the presence or ab-
sence of SP-D for 1 hr. After pre-incubation, eosinophils
were stimulated by various concentration of Dp solution
for 24 hrs. SP-D was boiled by 100°C for 10 min and
was used as heat-inactivated SP-D [24].Histology
Lung tissue was fixed in 10% formalin and embedded in
paraffin. Three-micrometer thick sequential sections
were performed. Sections for fibrosis were stained with
Gomori’s trichrome stain. Sequential sections were stained
with Luna-modified stain and TGF-β1 and IL-13 immu-
nohistochemistry (IHC). Both primary antibodies were
purchased from Abcam (Cambridge, UK). IHC were per-
formed as described previously [25]. Morphological ana-
lysis was performed quantitatively by Image J (National
Institutes of Health).Measurements of total protein and cytokine
concentrations
Harvested lungs were homogenized in lysis buffer (Cell
Signaling Technology, Inc. Danvers, MA) containing
1 mM phenylmethanesulfonyl fluoride (PMSF, Sigma-
Aldrich) using Savant FastPrep FP120 Homogenizer
(Thermo Scientific, Waltham, MA). Protein concentra-
tions were determined by the BCA method (Pierce,
Rockford, IL). Cytokines/growth factor were measured
with commercial ELISA kits (details were described in
Additional file 1). The values graphed for cytokine were
adjusted to the total protein concentration of the re-
spective lung samples.Collagen assay
Lungs were homogenized in 0.5 M acetic acid (50 vol-
umes to wet lung weight) containing about 1 mg/ml
pepsin (Sigma) using Savant FastPrep FP120 Homogenizer
(Thermo Scientific, Waltham, MA). Total lung collagen
was determined using the Sircol Collagen Assay kit
(Biocolor Ltd., Belfast, Northern Ireland) according to
the manufacturer’s instructions. The values graphed for
collagen were adjusted to the total protein concentra-
tion of the respective lung samples.
Flow cytometry
The lungs were minced and enzymatically digested
(DNAse and Collagenase) for 1 hr at 37°C. Cells were
stained by various fluorescence conjugated -antibodies
(details were described in Additional file 1). The stained
cells were analyzed by FACS using a BD LSRII and BD
FACS Canto II (San Diego, CA) for acquisition.
Statistical analysis
Comparisons between groups were analyzed using
one-way ANOVA with post-hoc Tukeys analysis. Some
comparisons between groups made with Student T-test
without ANOVA (GraphPad Prism, version 5.0; GraphPad
Software, Inc., San Diego, CA). Data are presented as
mean ± SEM. Differences were considered statistically sig-
nificant if p values were less than 0.05.
Results
Sub-epithelial airway fibrosis in Dp challenged mice
Chronic Dp exposure increased sub-epithelial fibrosis
in Dp-challenged WT and SP-D−/− mice compared to
PBS challenged mice (Figure 2A). When compared with
Dp-challenged WT mice, Dp-challenged SP-D−/− mice
demonstrate markedly increased sub-epithelial fibrosis
after chronic exposure (Figure 2A). The thickness of sub-
epithelial fibrosis was increased in all Dp-challenged
groups when compared to PBS challenged groups.
However, the thickness of sub-epithelial fibrosis of Dp
challenged SP-D−/− mice was significantly greater than
that of Dp-challenged WT mice (Figure 2B). Likewise,
the amount of collagen in the lungs of Dp-challenged
SP-D−/− mice was significantly increased compared to
the lungs of Dp-challenged WT mice and PBS-challenged
SP-D−/− mice (Figure 2C).
Cellular inflammation in Dp-challenged mice
Differential cell counts from the bronchial alveolar lav-
age fluid (BALF) and cytokine/growth factor concentra-
tions in BALF and whole lungs were examined to
evaluate the allergic inflammation of DP-challenged
mice. Although there were no observed differences in
the number of lymphocytes in BALF among both groups
of Dp-challenged mice, the total cells, eosinophils, and
Figure 2 Sub-epithelial airway fibrosis in SP-D−/− mice after Dp chronic exposure. (A) Representative photomicrographs of lungs from either
wild-type (WT) C57BL/6 mice or SP-D−/− mice stained with Gomori’s trichrome on day 42 after PBS or Dp challenge. Vertical rows were arranged by
group and horizontal rows were results representative of 3 independent experiments. Magnification: 100x. Scale bar = 200 μm. Dp/PBS: Dp sensitized
and PBS challenged mice. Dp/Dp: Dp sensitized and Dp challenged mice. (B) Morphological analysis of sub-epithelial fibrosis. (C) Collagen content in
the lungs of SP-D−/− mice or C57BL/6 (WT) mice on day 42 after saline or Dp challenge. Subepithelial fibrosis thickness and collagen production was
measured as described in Material and Methods. Data are presented as means ± SEM obtained from 3 different experiments. 3–5 mice per group were
used in each experiment (N = 10-15). White bars: PBS-challenged mice in each group, Black bar: Dp-challenged WT mice. Shaded bar: Dp-challenged
SP-D−/− mice. *p < 0.05.
Figure 3 BAL fluid cell analysis and cytokine concentration in Dp-challenged SP-D−/− mice. (A) Bronchoalveolar lavage (BAL) was performed
for total cell count and differentials. (B); Level of TGF-β1 in BAL fluid. (C) Level of TGF-β1 and Th2 cytokines in lung homogenate. Cytokines in BAL and
lung homogenates was measured by ELISA. Data are presented as means ± SEM obtained from 3 different experiments. 3–5 mice per group
were used in each experiment (N = 9-14). White bars: PBS challenged mice in each groups. Black bar: Dp challenged WT mice. Shaded bar: Dp
challenged SP-D−/− mice. *p < 0.05.
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Dp-challenged SP-D−/− mice when compared to Dp-
challenged WT mice, (Figure 3A).
TGF-β1 is recognized to be a key cytokine driving fi-
brotic lung disease [16]. Total TGF-β1 concentration
in BALF of Dp challenged SP-D−/− mice was signifi-
cantly increased when compared to Dp-challenged WT
mice and PBS challenged SPD−/− mice (Figure 3B).
Active TGF-β1 of lung homogenate in Dp challenged
SP-D−/− mice tended to increase when compared to
Dp-challenged WT mice although there are no statisti-
cally significant differences observed (Figure 3C).
These findings suggest that functional TGF-β1 was
produced around inflammatory site of lung in SP-D
deficient mice.
Several Th2 cytokines, IL-4, IL-5 and IL-13, were un-
detectable in BALF, but were present in the lung ho-
mogenates. While there were no detectable differences
in IL-4 and IL-5 between both groups of Dp-challenged
mice, SP-D−/− mice had significantly increased IL-13 pro-
duction when compared to WT after Dp-challenge
(Figure 3C).Figure 4 Th2/Th1 cell population in Dp challenged mice. Th2/Th1cell po
contour plots of CD3+ CD4+ lymphocytes from lung digests, among the 4 m
CD3 and CD4. Data was representative in 3 different experiments, with n = 3
positive Th cells population. IL-4/IFN-γ positive cells were analyzed in CD3 + C
CD4+ T cells of lung digests were analyzed by flow cytometry. Data were rep
means ± SEM of 3–5 mice per group. White bars: PBS challenged mice in eac
SP-D−/− mice. (D): mean fluorescence intensity (MFI) of IL-4 per T cell basis. (
different experiments, with n = 3 to 5 mice per condition. Stippled line: nega
challenged line. MFI: mean fluorescence intensity.Th2/Th1 cell population and cytokines in Dp-challenged
mice
To determine whether Th lymphocytes affected IL-13
production in SP-D−/− mice, we examined the intracel-
lular cytokine profile of Th2/Th1 cells that were present
in the total CD4+ cell population (CD3+/CD4+) from
the homogenized and digested lung tissue by flow cy-
tometry (Figure 4A). Although, the percentage of IL-4+
T cells trended towards an increase by Dp exposure
when compared with PBS challenged mice, there were
no detectible differences in percentage of IL-4+ T cells
between either group of Dp-challenged mice (Figure 4B).
Additionally, there were no detectible differences in the
number of IFN-γ + T cells from lung tissue between all
groups of mice (Figure 4C). To determine Th2/Th1
cytokine production per T cells basis, we analyzed mean
fluorescence intensity (MFI) of IL-4 and IFN-γ per cell
basis. MFI of IL-4 in Dp challenged SPD−/− mice was
only slightly increased compared to PBS challenged
SPD−/− mice, and appears to be within 2 fold increase
compared to Dp challenged WT mice (Figure 4D).
There were no detectable differences in MFI of IFN-γpulation were examined by flow cytometry. (A): Gating information and
ice groups. Lymphocytes were initially examined for dual expression of
to 5 mice per condition. (B): IL-4 positive Th cells population. (C): IFN-γ
D4 T cells. Percent of intracellular cytokine positive cells relative to CD3 +
resentative across 3 independent experiments and were presented as
h groups. Black bar: Dp challenged WT mice. Shaded bar: Dp challenged
E): MFI of IFN-γ per cell basis. per cell basis. Data was representative in 3
tive control IgG. Blue solid line: PBS challenged mice. Red bold line: Dp
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results, we did not observe detectible differences in
Th2/Th1 lymphocyte populations and Th2/Th1 cyto-
kines in SP-D−/− mice, which suggests that Th2/Th1
lymphocytes may not be a major contributor to the SP-
D-dependent IL-13 production.
Treatment with exogenous SP-D in Dp-challenged mice
To determine whether loss of SP-D directly affected
the increase of sub-epithelial fibrosis, exogenous SP-D
was administrated oropharyngeally into SP-D−/− mice
(SP-D rescue treatment mice, SP-D−/− Res). Again, we
observed that sub-epithelial fibrosis in SP-D−/− mice
was increased by chronic Dp exposure as compared to
WT Dp exposed mice. However, in Dp-challenged SP-
D−/− mice given the SP-D rescue treatment, sub-
epithelial fibrosis was attenuated (Figure 5A). Similarly,Figure 5 Sub-epithelial fibrosis in Dp-challenged mice with treatment of
C57BL/6 WT, SP-D−/−, and SP-D−/− with SP-D rescue treatment were stained w
100x. Scale bar =200 μm. Dp/PBS: Dp-sensitized and PBS-challenged mice
analysis of sub-epithelial fibrosis. Sub-epithelial fibrosis thickness was mea
in lungs of C57/B6 (WT), SP-D−/−, and SP-D−/− with SP-D rescue treatment a
Sircol collagen assay. In these bar graphs (B and C), data are presented as me
were used in each experiment (N = 6-13). White bars: PBS challenged mi
challenged SP-D−/− mice. Dotted bars: Dp challenged SP-D−/− mice wit
Student T-test.the thickness of sub-epithelial fibrosis surrounding the
bronchus was significantly reduced in Dp-challenged
SP-D−/− mice given SP-D rescue treatment when
compared to Dp-challenged SP-D−/− mice given ve-
hicle control (Figure 5B). The concentration of colla-
gen in the lungs of Dp challenged SP-D−/− mice was
significantly increased compared to that of Dp-
challenged WT mice. SP-D rescue treatment also sig-
nificantly decreased collagen concentration in lungs of
Dp-challenge SP-D−/− mice (Figure 5C). Moreover,
SP-D rescue treatment also significantly decreased the
cellular inflammation (Figure 6A) and total TGF-β1 of
BALF (Figure 6B) of Dp-challenged SP-D−/− mice as
compared to vehicle treated controls. We observed
similar patterns that the increases of both active TGF-
β1 and IL-13 in SP-D−/− were reduced by SP-D rescue
treatment (Figure 6C and D).exogenous SP-D. (A) Representative photomicrographs of lungs from
ith Gomori’s trichrome on day 42 after PBS or Dp-challenge. Magnification:
. Dp/Dp: Dp-sensitized and Dp-challenged mice. (B) Morphological
sured as described in Material and Methods. (C) Collagen production
nd on day 42 after saline or Dp challenge. Collagen was determined by
ans ± SEM obtained from 3 different experiments. 3–5 mice per group
ce in each groups. Black bar: Dp challenged WT mice. Shaded bar: Dp
h SP-D rescue. *p < 0.05 ANOVA with post-hoc Tukeys; †p < 0.05
Figure 6 BAL fluid cell analysis and cytokine concentration in Dp-challenged mice with treatment of SP-D. (A) BAL was performed for
total cell count, macrophages and eosinophils. (B); Level of total TGF-β1 in BAL fluid. (C); level of active TGF-β1 in lung homogenate. (D); level of
IL-13 in lung homogenate. Cytokines in BAL and lung homogenates was measured by ELISA. Data are presented as means ± SEM obtained from
3 different experiments. 3–5 mice per group were used in each experiment (N = 7-13). White bars: PBS challenged mice in each groups. Black
bar: Dp challenged WT mice. Shaded bar: Dp challenged SP-D−/− mice. *p < 0.05.
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of Dp-challenged mice
Previous reports have shown that allergic inflammation,
including eosinophilia, is related to the establishment
of airway remodeling [26,27]. In our studies, histological
examination with Luna modified stain demonstrated that
peribronchiolar eosinophils (red in cytoplasm) were
present in all groups of Dp-challenge mice when com-
pared to PBS-challenged mice (Figure 7A). However,
the number of tissue eosinophils was increased in Dp-
challenged SP-D−/− mice when compared to Dp-
challenged WT mice (Figure 7B). SP-D rescue treatment
also significantly decreased the eosinophil infiltration into
the tissue of Dp-challenged SP-D−/− mice (Figure 7B). In
order to determine if eosinophils are the source of TGF-
β1 and IL-13 in Dp-challenged SP-D−/− mice, we per-
formed Luna-modified stain and immunohistochemistry
using sequential staining techniques. Using this tech-
niques, we are able to show that many of the infiltrated
eosinophils which are positive for Luna-modified stain,
are also positive for TGF-β1 (blue arrows) and for IL-
13 (red arrows) (Figure 7A). As shown in Table 1, while
the percentage of TGF-β1 positive and IL-13 positive
eosinophils was similar among the groups, the total
number of TGF-β1 positive and IL-13 positive eosino-
phils was significantly increased in SPD−/− micecompared to WT and SP-D−/− rescue mice. Interest-
ingly, bronchial epithelial cells were also positive for
TGF-β1 (Figure 7A). Since the percentage of TGF-β1
positive epithelial cells was not increased in SP-D−/−
mice (Table 1), this suggests that epithelium derived
TGF-β1 may not be affected by SP-D in this model.
These findings further support the notion that eosino-
phils are an important source of both TGF-β1 and IL-
13 and may be regulated by SP-D.
SP-D regulates eosinophil-derived TGF-β1 and IL-13
To determine if SP-D directly regulates eosinophil func-
tion, in vitro experiments were performed with purified
eosinophils that were stimulated with Dp in the presence
or absence of SP-D. Dp-stimulation significantly increased
TGF-β1 production from eosinophils in a dose dependent
manner (Figure 8A). Interestingly, SP-D pre-treatment of
eosinophils significantly reduced TGF-β1 production at
both 2 μg/ml and 5 μg/ml doses (Figure 8A). Heat-
inactivated SP-D is less effective in inhibiting TGF-β pro-
duction from eosinophils when compared to multimeric
SP-D (Figure 8B). In addition, IL-13 production by iso-
lated eosinophils was also significantly increased by Dp
stimulation in a dose dependent manner, which was sig-
nificantly reduced by SP-D co-incubation (Figure 8B).
Taken together, these results demonstrate that SP-D can
Figure 7 Eosinophil infiltration and TGF-β1 and IL-13 production in lungs of Dp-challenged mice. (A) Photomicrographs of Luna staining
(eosinophils) and immunohistochemistry for TGF-β1 and IL-13. Photographs were representative in 3 different experiments. Magnification: 400x. Scale
bar =50 μm. Sequential staining were performed between Luna staining and immunohistochemistry for TGF-β1and IL-13. Blue arrows: TGF-β1 positive
eosinophils; Red arrows: IL-13 positive eosinophils. Dp/PBS: Dp-sensitized and PBS-challenged mice. Dp/Dp: Dp-sensitized and Dp-challenged
mice. (B) Morphological analysis of eosinophil infiltration in lungs Eosinophils under the sub-epithelial region were counted as described in Material and
Methods. Data are presented as mean ± SEM obtained from 3 different experiments. 3–5 mice per group were used in each experiment (N = 7-11). White
bars: PBS challenged mice in each groups. Black bar: Dp challenged WT mice. Shaded bar: Dp challenged SP-D−/− mice. Dotted bars: Dp
challenged SP-D−/− mice with SP-D rescue. *p < 0.05.
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and IL-13 production.
TGF-β blockade inhibits sub-epithelial fibrosis in the SP-D
deficient animal
In order to determine whether TGF-β1 affected sub-
epithelial fibrosis in the SP-D−/− mice, we blocked TGF-
β1 in our Dp model. Treatment with TGF-β blocking
antibody significantly reduced total and active TGF-β1
concentrations as measured in the BALF and whole lung
homogenate (Figure 9A). TGF-β1 blockade reduced sub-
epithelial fibrosis in both strain of Dp-challenge mice
compared to Dp-challenge mice given the IgG isotype
control administration (Figure 9B). Additionally, the thick-
ness of sub-epithelial fibrosis in Dp challenged SP-D−/−
mice with TGF-β1 Ab treatment was significantly reduced
compared to Dp-challenged SP-D−/− mice given the IgGTable 1 Histological data of eosinophils and epithelial cells b
TGF + Eo % of TGF + Eo
(No./mm) (%)
WT Dp/Dp 7.67 ± 1.90 42.34 ± 3.71
SPD−/− Dp/Dp 14.51 ± 1.92* 41.91 ± 3.90
SPD−/− rescue Dp/Dp 9.06 ± 1.45† 40.38 ± 4.29
TGF-β1 and IL-13 were stained by immunohistochemistry (IHC). Methods to evaluat
means ± SEM obtained from 3 different experiments. 3–5 mice per group were used
Dp-challenged mice). *: P < 0.05 compared with Wt mice. †: P < 0.05 compared withisotype control treatment (Figure 9C). The inhibitory ef-
fect of anti-TGF-β treatment in SPD−/− mice was higher
than that in WT mice (WT vs SP-D−/−; 31.7% reduced vs
50.0% reduced, respectively) (Figure 9C). Collagen con-
centrations were also significantly decreased in SP-D−/−
Dp challenged lungs that had been given TGF-β1 Ab
treatment when compared to those given IgG isotype
control treatment (Figure 9D). Interestingly, TGF-β1
Ab treatment significantly decreased IL-13 concentra-
tion in SP-D−/− mice, although it was not effective for
WT mice (Figure 9E). These results support that TGF-
β1 is key cytokine in establishing Dp-induced sub-
epithelial fibrosis in mice that lack functional SP-D.
Discussion
Sub-epithelial fibrosis is a major complication of chronic
allergic airways disease and can result in fixed air-flowy IHC
IL13 + Eo % of IL13 + Eo % of TGF + epithelial cells
(No./mm) (%) (%)
8.41 ± 1.79 41.83 ± 3.87 88.35 ± 5.14
15.32 ± 2.59* 41.58 ± 4.31 91.65 ± 3.68
8.65 ± 1.32† 37.34 ± 2.43 97.07 ± 1.31
e the IHC stain were described in Material and Methods. Data are presented as
in each experiment (N = 7-11). Eo: eosinophils. Dp/Dp: Dp-sensitized and
SPD−/− mice.
Figure 8 SP-D regulates eosinophil-derived TGF-β1 and IL-13. Effect of SP-D on eosinophils-derived TGF-β1 and IL-13 production was examined
in vitro experiment. (A): Level of total TGF-β1 in eosinophil culture supernatant. (B): Level of total TGF-β1 in supernatant of eosinophil cultures
in the presence of normal and heat inactivated SP-D. (C): Level of IL-13 in eosinophil culture supernatant. Eosinophils from IL-5 transgenic
mice were incubated in vitro with Dp for 24 hr in the presence or absence of SP-D pre-incubation as described Material and Methods. TGF-β1
and IL-13 in culture supernatants was determined by ELISA. Data are presented as means ± SEM obtained from 2 different experiments (N = 6). White
bars: control. Black bars: Dp stimulation at different concentrations. Shaded bars: Dp stimulation with SP-D pre-incubation at different concentrations.
*p < 0.05.
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molecular mechanisms resulting in sub-epithelial fibrosis
and effective therapeutic interventions remains limited.
Utilizing a mouse model of chronic challenge to clinic-
ally relevant house dust mite, we demonstrate a central
role of SP-D in the development of sub-epithelial fibro-
sis. Our new findings support that SP-D regulates the
number of tissue eosinophils and the level of eosinophil-
derived TGF-β1 and IL-13. Together our findings pro-
vide novel evidence supporting that functional SP-D can
protect allergic airways from the development of sub-
epithelial fibrosis.
TGF-β is known as a key cytokine of collagen produc-
tion in fibrotic disease including airway remodeling in
asthma [16,21]. TGF-β can induce differentiation of fi-
broblasts to myofibroblasts, which can contribute to col-
lagen deposition [28] and production of growth factors
[29,30]. Previous reports demonstrated anti TGF-β1 orsmad3 neutralizing antibody treatment reduced airway re-
modeling in OVA chronic exposure model [31,32]. In our
findings, TGF-β1 production was increased in SP-D−/−
mice, contributing to enhance sub-epithelial fibrosis.
Interestingly, SP-D can bind to allergens including Dp [6].
Therefore, if functional SP-D is absent, unbound Dp anti-
gen may be a trigger that leads to enhanced TGF-
β1production and sub-epithelial fibrosis as observed in
SP-D−/− mice.
Previous work has suggested that sub-epithelial fibro-
sis after chronic challenge to house dust mite antigen
was independent of either eosinophils or TGF-β1
[33,34]. In that context, our observation that anti-TGF-
β1 antibody treatment reduced sub-epithelial fibrosis
and collagen production in the Dp-challenged SP-D de-
ficient mice was quite unexpected. One explanation is
that the previous studies used mice that were sufficient
in SP-D and the involvement of eosinophils and/or
Figure 9 Anti-TGF-β1 antibody treatment of Dp-challenged C57BL/6 and SP-D−/−mice. SP-D−/−mice were treated with an anti TGF-β1 antibody
and IgG isotype control to examine whether TGF-β1 was important for sub-epithelial fibrosis. (A): Total TGF-β1 in BALF and active TGF-β1 in
lung homogenates. (B): Photomicrographs of lungs stained with Gomori’s trichrome. They were representative of 3 different experiments.
Magnification: 100x. Scale bar =200 μm. Dp/IgG: Dp sensitized and Dp challenged mice with IgG treatment. Dp/TGFβAb: Dp sensitized and Dp
challenged mice with TGF-β antibody treatment. (C): Subepithelial fibrosis thickness. (D): Collagen production in lungs determined by Sircol collagen
assay. (E): Level of IL-13 in lungs determined by ELISA. In these bar graphs (A,C,D and E), data are presented as mean ± SEM obtained from 2 different
experiments. 3–5 mice per group were used in each experiment (N = 6-8). Black bars: Dp challenged WT and SP-D−/− mice treated with IgG isotype
control. Shaded bars: Dp challenged WT and SP-D−/− mice treated with an anti-TGF-β1 antibody. *p < 0.05 ANOVA with post-hoc Tukeys; †p < 0.05
Student T-test.
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Alternatively, IL-13 is recognized as a Th2 cytokine that
can contribute to sub-epithelial fibrosis and a pro-fibrotic
cytokine in lung diseases [35]. IL-13 depletion can reduce
sub-epithelial fibrosis and epithelial hypertrophy in
chronic asthma model [36,37]. Fattouh et al. demon-
strated that IL-13 was important for airway fibrosis inde-
pendent of TGF-β signaling in Th2 associated disease
[34,38]. Our findings demonstrated that IL-13 production
was increased in Dp-challenged SPD−/− mice and SP-D
rescue decrease these responses similar to previous obser-
vations [34]. In addition, our findings demonstrate that
anti-TGF-β1 antibody treatment decreased IL-13 produc-
tion in lung homogenate in SPD−/− mice (Figure 9),
which suggests a potential synergistic role between TGF-
β1 and IL-13 in airway remodeling when SP-D is absent.
A previous study found that administration of a soluble
TGF-β receptor-Fc molecule ameliorated IL-13-induced
fibrosis [39], supporting this paradigm. Recent reports
also showed that inhibition of TGF-β1/smad3 signaling
can lead to decrease IL-13 production in lung diseases
[40,41]. Similar mechanism seems to occur in the lung
of SP-D−/− mice, which warrant further study.In either chronic antigen exposure asthma model or
gene-modified model, both peribronchial fibrosis and
TGF-β production were related to eosinophils [26,27]. In
airways of asthmatic patients, 75-80% of TGF-β1 mRNA
expression positive cells were eosinophils [42,43]. On
the other hand, it is known that bronchial epithelial cells
were also source of TGF-β1 in asthma [44]. In OVA
challenged model, bronchial epithelium-derived TGF-β1
was enhanced sub-epithelial fibrosis [31]. Therefore, we
examined what type of cells that are a potential source
of TGF-β1 and as target cells by SP-D in this model. In
the present findings, TGF-β1 expressing eosinophils
were increased in Dp-challenged SP-D−/− mice. More-
over, we identified that SP-D directly suppress the pro-
duction of eosinophil derived TGF-β. To our knowledge,
this is the first report to demonstrate a direct function
of SP-D on eosinophils response to antigen. In contrast,
our findings showed that TGF-β1 expression in bron-
chial epithelial cells of SP-D−/− mice were not signifi-
cant difference among the 3 groups unlike TGF
expression in eosinopils (Figure 7 and Table 1). Based on
these results, our findings suggest that a target of SP-D
in Dp-induced sub-epithelial fibrosis may be the acti-
vated eosinophils that produce TGF-β1. In addition to
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uated IL-13 production from Dp stimulated eosinophils.
Since we did not identify an increase Th2 cells in the
lung tissue from SP-D−/− mice, our findings suggest
that eosinophils may be also an important source of IL-
13 as reported in other model systems [45]. Taken to-
gether, our findings support that functional SP-D regu-
lates both the tissue infiltration and function of
eosinophils, resulting in protection of the airways against
development of sub-epithelial fibrosis. Our findings ex-
tend the functional role of SP-D in allergic airways disease
beyond regulation of eotaxin-triggered chemotaxis and
degranulation of eosinophils [46], induction of apoptosis
in eosinophils, and enhanced uptake of eosinophils by
macrophages [47].
The molecular mechanism that SP-D inhibited TGF-β1
and IL-13 production by Dp-activated eosinophils also re-
mains unknown. Previous reports have shown that inter-
stitial eosinophils express high levels of signal regulatory
protein (SIRP)-α, an inhibitory receptor of SP-D, and that
cross-linking of SIRP-α on the surface of eosinophils sig-
nificantly reduced the amount of eosinophil peroxidase re-
leased during stimulation with a calcium ionophore [48].
In macrophages under normal condition, SP-D binds
SIRP-α, leading to inhibit p38 activation, which induces
cytokine production via Src homology region 2 domain-
containing phosphatase (SHP)-1 [49,50]. It remains un-
known whether similar events occur in eosinophils during
chronic allergic inflammatory conditions. Since Toll-like
receptor (TLR) 4 is candidate of receptor of Dp [51], it is
possible that SP-D bind Dp directly in order to block Dp
binding to TLR4. Alternatively, SP-D may also interfere
with signaling by binding directly to TLR4. Understanding
the molecular mechanisms that SP-D regulates eosinophil
function will be the focus of future investigations.
In conclusion, we identify that SP-D regulates eosino-
phil production of both IL-13 and TGF-β after stimula-
tion with Dp, mitigating sub-epithelial fibrosis which is
an important component of airway remodeling in
chronic allergic airways disease. Appreciation of the
functional role of SP-D during allergic airways disease
is high clinical significance since a better understanding
of how to attenuate the severity of sub-epithelial fibro-
sis could lead to better treatment options.Additional file
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